Aquestive(AQST)
Search documents
Aquestive(AQST) - 2019 Q1 - Earnings Call Transcript
2019-05-11 12:01
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Daniel Barber - Chief Strategy and Development Officer John Maxwell - Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Thomas Flaten - Lake Street Capital Ram Selvaraju - ...
Aquestive(AQST) - 2019 Q1 - Quarterly Report
2019-05-08 17:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technology Dr ...
Aquestive(AQST) - 2018 Q4 - Earnings Call Transcript
2019-03-15 03:26
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2018 Earnings Conference Call March 14, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Dan Barber - Chief Strategy and Development Officer John Maxwell - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Douglas Buchanan ...
Aquestive(AQST) - 2018 Q4 - Annual Report
2019-03-14 18:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3827296 (State or ...